BioLife Solutions, Inc. (NASDAQ:BLFS) Holdings Cut by Portolan Capital Management LLC

Portolan Capital Management LLC lowered its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 57.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 427,876 shares of the medical equipment provider’s stock after selling 576,352 shares during the quarter. Portolan Capital Management LLC owned about 0.92% of BioLife Solutions worth $10,714,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at approximately $28,000. 1620 Investment Advisors Inc. acquired a new stake in shares of BioLife Solutions in the second quarter valued at approximately $35,000. Isthmus Partners LLC increased its stake in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares during the period. Quest Partners LLC acquired a new stake in shares of BioLife Solutions in the third quarter valued at approximately $57,000. Finally, GAMMA Investing LLC increased its stake in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Buying and Selling

In related news, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the sale, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total transaction of $232,800.00. Following the sale, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. The trade was a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,313 shares of company stock worth $1,572,899. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Down 1.7 %

Shares of NASDAQ:BLFS opened at $26.81 on Wednesday. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -25.29 and a beta of 1.91. BioLife Solutions, Inc. has a 1-year low of $12.45 and a 1-year high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a 50 day moving average price of $24.32 and a 200 day moving average price of $23.32.

Analyst Ratings Changes

BLFS has been the topic of several analyst reports. Northland Securities raised their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. TD Cowen raised their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright lowered their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.